On August 18, 2016 Nordic Nanovector ASA (OSE: NANO), a biotechnology company focusing on the development of novel targeted therapeutics in haematology and oncology, reported that the first cohorts of both Arm 3 and 4 of the expanded Lymrit 37-01 clinical study with Betalutin have been completed (Press release, Nordic Nanovector, AUG 18, 2016, http://www.nordicnanovector.com/article/Nordic-Nanovector-completes-recruitment-of-the-first-cohorts-of-Arm-3-and-Arm-4-of-expanded-Phase-1-2-study-of-Betalutin-in-NHL-patients/2277398 [SID:1234514641]). Betalutin is a novel anti-CD37 targeting Antibody Radionuclide Conjugate in development for the treatment of major types of non-Hodgkin lymphoma (NHL), including Follicular Lymphoma (FL). Schedule your 30 min Free 1stOncology Demo! Arm 3 is investigating the safety and efficacy of Betalutin in relapsed FL patients pre-dosed with standard anti-CD20 immunotherapy (rituximab) on Day 0, a few hours prior to the administration of 15 MBq/kg Betalutin. Arm 4 is investigating the safety and efficacy of Betalutin in relapsed FL patients pre-dosed with high-dose unconjugated "cold" lilotomab (previously referred to as HH1) anti-CD37 antibody on Day 0, a few hours prior to the administration of 15 MBq/kg Betalutin.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Luigi Costa, Nordic Nanovector CEO, commented: "We are pleased to have completed the first cohorts of both Arm 3 and Arm 4 of the expanded Lymrit 37-01 study. These arms are designed to investigate if different pre-dosing regimens will allow the use of higher doses of Betalutin to potentially achieve even better efficacy and an even more compelling product profile. The role of pre-dosing is to potentially ensure better control of haematological side effects and more specific tumour targeting with Betalutin."
A potential decision to increase the dose of Betalutin to 17.5 MBq/kg or 20 MBq/kg in one or the other arm can be made based on the evaluation of the safety and efficacy data observed in these first 3 patients of both arm.
The Lymrit 37-01 study is a Phase 1/2 open label, single injection ascending dose study investigating three dose levels of Betalutin and different pre-dosing regimens in patients with relapsed NHL with the aim of identifying an optimal dose regimen to take into the Phase 2 PARADIGME study, which is expected to start in 2H 2017.